Home › Compare › AVRO vs BTI

AVRO vs BTI: Dividend Comparison 2026

AVRO yields 142.86% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVRO wins by $19.51M in total portfolio value
10 years
AVRO
AVRO
● Live price
142.86%
Share price
$1.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.55M
Annual income
$8,225,014.26
Full AVRO calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — AVRO vs BTI

📍 AVRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVROBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVRO + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AVRO pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVRO
Annual income on $10K today (after 15% tax)
$12,142.86/yr
After 10yr DRIP, annual income (after tax)
$6,991,262.12/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, AVRO beats the other by $6,988,893.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVRO + BTI for your $10,000?

AVRO: 50%BTI: 50%
100% BTI50/50100% AVRO
Portfolio after 10yr
$9.79M
Annual income
$4,113,900.45/yr
Blended yield
42.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

AVRO
Analyst Ratings
4
Buy
6
Hold
Consensus: Hold
Altman Z
-0.7
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVRO buys
0
BTI buys
0
No recent congressional trades found for AVRO or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVROBTI
Forward yield142.86% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$19.55M$37.7K ✓
Annual income after 10y$8,225,014.26 ✓$2,786.64
Total dividends collected$18.03M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: AVRO vs BTI ($10,000, DRIP)

YearAVRO PortfolioAVRO Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$24,986$14,285.71$11,299$598.92+$13.7K → AVRO
2$60,093$33,358.76$12,794$703.91+$47.3K → AVRO
3$139,283$74,982.82$14,518$829.07+$124.8K → AVRO
4$311,456$162,423.26$16,513$978.64+$294.9K → AVRO
5$672,698$339,440.31$18,827$1,157.84+$653.9K → AVRO
6$1,404,965$685,177.81$21,518$1,373.12+$1.38M → AVRO
7$2,840,723$1,337,410.52$24,657$1,632.46+$2.82M → AVRO
8$5,566,801$2,527,227.75$28,329$1,945.74+$5.54M → AVRO
9$10,584,947$4,628,469.98$32,637$2,325.33+$10.55M → AVRO
10$19,550,908$8,225,014.26$37,708$2,786.64+$19.51M → AVRO

AVRO vs BTI: Complete Analysis 2026

AVRO — Stock

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full AVRO Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this AVRO vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVRO vs SCHDAVRO vs JEPIAVRO vs OAVRO vs KOAVRO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.